We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection.
- Authors
Read, Tim R. H.; Jensen, Jørgen S.; Fairley, Christopher K.; Grant, Mieken; Danielewski, Jennifer A.; Su, Jenny; Murray, Gerald L.; Chow, Eric P. F.; Worthington, Karen; Garland, Suzanne M.; Tabrizi, Sepehr N.; Bradshaw, Catriona S.
- Abstract
High levels of macrolide resistance and increasing fluoroquinolone resistance are found in Mycoplasma genitalium in many countries. We evaluated pristinamycin for macrolide-resistant M. genitalium in a sexual health center in Australia. Microbiologic cure was determined by M. genitalium-specific 16S PCR 14-90 days after treatment began. Of 114 persons treated with pristinamycin, infection was cured in 85 (75%). This percentage did not change when pristinamycin was given at daily doses of 2 g or 4 g or at 3 g combined with 200 mg doxycycline. In infections with higher pretreatment bacterial load, treatment was twice as likely to fail for each 1 log10 increase in bacterial load. Gastrointestinal side effects occurred in 7% of patients. Pristinamycin at maximum oral dose, or combined with doxycycline, cured 75% of macrolide-resistant M. genitalium infections. Pristinamycin is well-tolerated and remains an option where fluoroquinolones have failed or cannot be used.
- Subjects
MYCOPLASMA diseases; MACROLIDE antibiotics; DIAGNOSTIC microbiology; DRUG side effects; DOXYCYCLINE; THERAPEUTICS; PEPTIDES; ANTIBIOTICS; COMPARATIVE studies; DRUG resistance in microorganisms; RESEARCH methodology; MEDICAL cooperation; MYCOPLASMA; RESEARCH; EVALUATION research; PHARMACODYNAMICS
- Publication
Emerging Infectious Diseases, 2018, Vol 24, Issue 2, p328
- ISSN
1080-6040
- Publication type
journal article
- DOI
10.3201/eid2402.170902